Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2018 March;30(1) > Minerva Biotecnologica 2018 March;30(1):22-8

CURRENT ISSUE
 

ARTICLE TOOLS

Publication history
Reprints
Cite this article as

MINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,25


eTOC

 

REVIEW  FREEfree


Minerva Biotecnologica 2018 March;30(1):22-8

DOI: 10.23736/S1120-4826.17.02276-5

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

ADAM17 and gastrointestinal tract diseases: clinical aspects with translational messages

Sharmila FAGOONEE 1, Rinaldo PELLICANO 2, Giovanni C. ACTIS 3

1 Molecular Biotechnology Center, Institute for Biostructures and Bioimages, National Research Council, University of Turin, Turin, Italy; 2 Unit of Gastroenterology, Molinette Hospital, Turin, Italy; 3 Medical Center Private Practice, Turin, Italy


PDF  


Vertebrate cells express a number of membrane markers including cytokines, chemokines, growth factors, and inflammatory signaling molecules. These markers go cleaved in a special process named “ectodomain shedding”, either to allow response to environmental changes, or to maintain intercellular dialogue. Their extracellular domain may retain specific activity, or can be changed into an inactive decoy molecule, whereas the inner domain translocates to the nucleus and interacts with the genome. This polyvalent cleavage is mediated by a particular protein family, ADAM (A disintegrin and metalloprotease) which acts as “molecular scissor.” The human proteome includes at least 22 functionally and structurally different ADAMs. In this review, we focus on ADAM17, a protease with a marked impact on physiologic activities and pathologic functions in the gastrointestinal tract.


KEY WORDS: ADAM proteins - ADAM17 protein - Gastrointestinal tract - Inflammatory bowel diseases

top of page

Publication History

Issue published online: December 6, 2017
Manuscript accepted: May 4, 2017
Manuscript received: April 27, 2017

Cite this article as

Fagoonee S, Pellicano R, Actis GC. ADAM17 and gastrointestinal tract diseases: clinical aspects with translational messages. Minerva Biotec 2018;30:22-8. DOI: 10.23736/S1120-4826.17.02276-5

Corresponding author e-mail

actis_g@libero.it